Introduction
============

Prostate cancer is the fifth most common malignancy in Korea ([@b1-ol-0-0-4459]), but the second most prevalent malignancy and the sixth leading cause of cancer-associated mortality in the global population ([@b2-ol-0-0-4459],[@b3-ol-0-0-4459]). A number of studies have been performed with regard to prostate cancer, but the pathogenesis of the disease remains unclear. The established prognostic factors for prostate cancer are the Gleason score (GS), pathological T (pT) staging and serum prostatic-specific antigen (PSA) level ([@b4-ol-0-0-4459]). Ki-67 and Myc proto-oncogene protein have also been documented as prognostic factors for biochemical recurrence (BCR), metastatic disease and cancer-related mortality ([@b5-ol-0-0-4459],[@b6-ol-0-0-4459]). However, these prognostic factors alone are not sufficient for predicting prognostic characteristics, including early stage or advanced prostate cancer, presence of metastasis or disease-related mortality. Thus, novel prognostic biomarkers have been suggested for prostate cancer management. Recently, biomarkers such as transcriptional regulator ERG (ERG), phosphatase and tensin homolog (PTEN), cysteine-rich secretory protein 3 (CRISP3) and serine protease inhibitor Kazal type I (SPINK1) have been considered useful prognostic factors, although contradictory results have been obtained with regard to BCR and cancer-related mortality. The mutual associations of these biomarkers remain to be verified, as the four biomarkers have not previously been studied together.

The purpose of the present study was to simultaneously evaluate the prognostic value and associations of four biomarkers, namely, ERG, PTEN, CRISP3 and SPINK1, and to conduct risk stratification of prostate cancer for patient management. This study is the first to research ERG, PTEN, CRISP3 and SPINK1 expression concurrently.

Materials and methods
=====================

### Clinical study samples and assessment

The use of clinical tumor samples was approved by the Institutional Review Board of the Kyung Hee University Hospital (Seoul, Korea). A total of 68 formalin-fixed, paraffin-embedded, prostate cancer samples from radical prostatectomies performed between January 2004 and December 2012, were obtained from Kyung Hee University Medical Center. The mean follow-up time was 49.2 months (range, 11--111 months). At the time of tumor sampling, none of the patients had been administered previous radiation therapy or chemotherapy, and there was no evidence of metastasis.

For all microscopy experiments, a BX53 microscope (Olympus Corporation, Tokyo, Japan) was used. The samples were reviewed by three pathologists from the hospital according to the pathological T (pT) staging of the American Joint Committee on Cancer 2010 criteria (7th edition) ([@b7-ol-0-0-4459]) and GS grading according to the International Society of Urological Pathology 2005 criteria ([@b8-ol-0-0-4459]). GSs were grouped as values of \<7, equal to 7, or \>7 (3-tiered system). GSs of 3+4 and 4+3 were combined ([@b9-ol-0-0-4459]). The demographics of the tumor samples are shown in [Table I](#tI-ol-0-0-4459){ref-type="table"}.

Following histological diagnosis, PSA tests were conducted. A PSA level with a second confirmatory level \>0.2 ng/ml was defined as BCR ([@b10-ol-0-0-4459]). The period from the time of surgical treatment to BCR represents the BCR-free survival time.

### Immunohistochemistry

Sections (5-µm thick) were cut from the formalin-fixed, paraffin-embedded tissue and stained with Leica auto-stainer Bond Max using the Bond Polymer Refine Detection System (Leica Biosystems Newcastle Ltd., Newcastle, UK) according to the manufacturer\'s protocols, with minor modifications. Briefly, the sections were deparaffinized by Bond Dewax Solution (Leica Biosystems Newcastle Ltd.), followed by heat-induced antigen retrieval using Bond Epitope retrieval solution 1 (for SPINK1) or 2 (for ERG, PTEN and CRISP3) (Leica Biosystems Newcastle Ltd.) for 20 min at 100°C. The endogenous peroxidase was quenched by incubation with hydrogen peroxide for 15 min. Sections were incubated for 15 min at ambient temperature with mouse monoclonal ERG (catalog. no. CM 421 A, C; Biocare Medical LLC, Concord, CA, USA) at a 1:100 dilution, with mouse monoclonal PTEN (CM 278 AK, CK; Biocare Medical LLC) at a 1:100 dilution, with rabbit polyclonal antibody CRISP3 (LS-B8285; LifeSpan Biosciences Inc., Seattle, WA, USA) at a 1:500 dilution, and with mouse monoclonal SPINK1 (ab58227; Abcam, Cambridge, MA, USA) at a 1:1,000 dilution. Bound primary antibodies were visualized using a biotin-free polymeric horseradish peroxidase-linker antibody conjugate system in a Bond-Max automatic slide stainer (Leica Biosystems Melbourne Pty. Ltd., Melbourne, Victoria, Australia). The nuclei of these sections were counterstained with hematoxylin in the Bond Polymer detection kit (Leica Biosystems, Newcastle, UK). Vascular endothelial cells for ERG and normal benign prostate gland and stroma cells for PTEN were based on healthy sites in the present patients and used as a positive internal control. Normal pancreatic tissues for CRISP3 and SPINK1 were obtained from the remaining tissues of patients that underwent a pancreatectomy due to chronic pancreatitis and used as an external positive control.

### Pathological analysis of immunohistochemistry

Immunohistochemistry results were assessed and scored by the intensity and proportion (fraction) of positive tumor cells. The staining intensity was graded as follows (4-tiered system): No staining, 0; only visible at high magnification, 1+; visible at low magnification, 2+; and striking at low magnification, 3+.

The final score for ERG expression was based on nuclear staining and was classified as follows ([@b11-ol-0-0-4459]): Negative, absence of ERG-stained cells; weak, intensity 1+ nuclear staining; moderate, intensity 2+ nuclear staining; and strong, intensity 3+ nuclear staining ([Fig. 1A](#f1-ol-0-0-4459){ref-type="fig"}). Only weak to strong staining was considered as positive for ERG.

The immunohistochemical scoring of PTEN staining was based on cytoplasmic staining as part of a 3-tiered system as follows ([@b12-ol-0-0-4459]): Grade 0, absence of PTEN-positive tumor cells; grade 1, less staining than that of the normal prostate gland tissue; and grade 2, equal to or stronger staining of the normal prostate gland tissue ([Fig. 1B](#f1-ol-0-0-4459){ref-type="fig"}).

Next, a final score for CRISP3 was evaluated according to cytoplasmic staining and was categorized as negative, weak, moderate or strong using the intensity score and proportion score of positive cells, as previously documented ([@b13-ol-0-0-4459],[@b14-ol-0-0-4459]): Negative, absence of CRISP3 staining in 100% of tumor cells; weak, intensity 1+ in \>70% of tumor cells, or intensity 2+ in ≤30% of tumor cells; moderate, intensity 1+ in \>70% of tumor cells, intensity 2+ in \>30 but ≤70% of tumor cells, or intensity 3+ in ≤30% of tumor cells; strong, intensity 2+ in \>70% of tumor cells or intensity of 3+ in \>30% of tumor cells ([Fig. 1C](#f1-ol-0-0-4459){ref-type="fig"}).

Cytoplasmic staining was also classified into negative and positive SPINK1 expression as follows (2-tiered system) ([@b15-ol-0-0-4459]): Negative, ≤5% stained cells; and positive, \>5% stained cells ([Fig. 1D](#f1-ol-0-0-4459){ref-type="fig"}).

Analyses were performed for the correlations of the two biomarkers (PTEN, CRISP3) with clinicopathological parameters, BCR and cancer-related mortalities using a binary system approach, grouping low expression (negative/weak for CRISP3; and grade 0/grade 1 for PTEN) vs. high expression (moderate/strong for CRISP3; and grade 2 for PTEN).

### Statistical analysis

Statistical analyses were performed using SPSS version 12.0 (IBM SPSS, Armonk, NY, USA). Pearson\'s χ^2^ test, Fisher\'s exact test and Student\'s t-test were conducted to determine correlations between the tested antibodies and clinicopathological parameters. Univariate survival analyses were performed to examine the prognostic significance of antibody expression and clinicopathological parameters, according to the Kaplan-Meier curve with a log-rank test. Multivariate survival analysis was conducted for all clinicopathological parameters and biomarkers, on the basis of the Cox proportional hazards model (95% confidence interval) with the forward stepwise elimination method. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Frequency of ERG, PTEN, CRISP3 and SPINK1 expression

From the tumor samples, positive ERG, low PTEN, high CRISP3 and positive SPINK1 expression was found in 18/68 (26.5%), 52/68 (76.5%), 42/68 (61.8%) and 21/68 (30.9%) samples, respectively.

### Associations between ERG, PTEN, CRISP3 and SPINK1 expression, and clinicopathological parameters

#### ERG expression

There was a non-significant trend between positive ERG expression and a GS of \<7. Positive ERG expression in patients with a GS of \<7 was noted in 6/19 samples (31.6%) compared with 12/49 samples (24.5%) in patients with a GS of ≥7 (P=0.575; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

#### PTEN expression

Significant associations existed between low PTEN expression and a high tumor volume and a high GS; low PTEN expression was associated with a significant increase in tumor volume (20.4±19.2%), compared with high PTEN expression (8.8±11.3%) (P=0.035; [Table II](#tII-ol-0-0-4459){ref-type="table"}). Low PTEN in patients with a GS of ≥7 was expressed in 41/49 samples (83.7%) vs. 11/19 samples (57.9%) in those with a GS of \<7 (P=0.020; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

It was observed that low PTEN expression occurred more frequently in prostate cancers with lymphovascular invasion (LVI), high pT stage, high pre-treatment PSA (prePSA) level, metastasis or cancer-related mortality, although the differences were not significant. Low PTEN expression occurred in 13/14 samples (92.9%) with LVI vs. 39/54 samples (72.2%) without LVI (P=0.105); in 25/30 samples (83.3%) in pT3 vs. 27/38 samples (71.1%) in pT2 (P=0.236); in 5/5 samples (100.0%) with metastasis vs. 42/57 samples (73.7%) without metastasis (P=0.191); and in 9/9 samples (100.0%) in decedents vs. 43/59 samples (72.9%) in living patients (P=0.076) ([Table II](#tII-ol-0-0-4459){ref-type="table"}). There was also a non-significant increase in prePSA (10.8±8.9 ng/ml) in samples with low PTEN, compared with samples (8.3±5.2 ng/ml) with high PTEN expression (P=0.303; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

#### CRISP3 expression

High CRISP3 expression was significantly correlated with high prePSA level and high pT stage; CRISP3 overexpression demonstrated a significant increase in prePSA (11.6±9.6 ng/ml) compared with low CRISP3 expression (7.9±4.6 ng/ml) (P=0.045; [Table II](#tII-ol-0-0-4459){ref-type="table"}). CRISP3 overexpression in pT3 was identified in 23/30 samples (76.7%) vs. 19/38 samples (50.0%) in pT2 (P=0.025; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

High CRISP3 expression was detected more frequently in prostate cancers with LVI than in those without, although the difference was not statistically significant; high CRISP3 expression was noted in 11/14 samples (78.6%) with LVI vs. 31/54 samples (57.4%) without LVI (P=0.146; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

#### SPINK1 expression

It was found that prostate cancers that were positive for SPINK1 expression tended to have high prePSA levels compared with those without SPINK1 expression, although the difference was not significant; an increase in prePSA (13.2±10.0 ng/ml) was noted in cancers that overexpressed SPINK1 compared with those that were negative for SPINK1 expression (8.8±6.9 ng/ml) (P=0.09; [Table II](#tII-ol-0-0-4459){ref-type="table"}). SPINK1 was not associated with any of the clinicopathological parameters.

#### Associations between ERG, PTEN, CRISP3 and SPINK1 expression

A significant inverse association between ERG, PTEN and SPINK1 expression was verified in the present study.

Low PTEN expression in prostate cancer with positive ERG expression was noted in 17/18 samples (94.4%) vs. 35/50 samples (70.0%) with negative ERG expression (P=0.036; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

SPINK1 expression was inversely associated with ERG expression; negative SPINK1 expression in tumor samples with positive ERG expression was detected in 18/18 (100.0%) vs. 29/50 samples (58.0%) with negative ERG expression (P=0.001; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

CRISP3 was overexpressed in ERG-positive prostate cancers, but with a non-significant positive trend; high CRISP3 expression in ERG-positive prostate cancer was shown in 14/18 samples (77.8%) vs. 28/50 samples (56.0%) in ERG-negative prostate cancer (P=0.103; [Table II](#tII-ol-0-0-4459){ref-type="table"}).

#### Analysis of BCR-free survival

A shorter BCR-free survival time was significantly associated with high GS (P=0.028), high pT stage (P\<0.001) and metastasis (P\<0.001) among the clinicopathological parameters ([Fig. 2A--C](#f2-ol-0-0-4459){ref-type="fig"}) upon univariate analysis (Kaplan-Meier curve and log-rank test). The other clinicopathological parameters of surgical margin, lymphovascular invasion and perineural invasion exhibited no significant statistical value for BCR-free survival.

It was also demonstrated that low PTEN and high CRISP3 expression were associated with decreased BCR-free survival (P=0.036 and P=0.002, respectively; [Fig. 2E and F](#f2-ol-0-0-4459){ref-type="fig"}) upon univariate analysis. Positive ERG expression was not significantly associated with BCR-free survival (P=0.889; [Fig. 2D](#f2-ol-0-0-4459){ref-type="fig"}). Therefore, as positive ERG expression was not associated with BCR compared with low PTEN or high CRISP3 expression, this strengthened the hypothesis that positive ERG expression is present in early-stage prostate cancer ([@b16-ol-0-0-4459],[@b17-ol-0-0-4459]). However, the PTEN and CRISP3 biomarkers did not exhibit prognostic value for BCR-free survival upon the multivariate analysis (Cox\'s proportional hazard model).

#### Defining low- and high-risk subgroups, and correlation of subgroups with BCR

On the basis of the aforementioned results, low-risk and high-risk subgroups were created; the high-risk subgroup was defined as prostate cancer cases with low PTEN and high CRISP3 expression, and the low-risk subgroup was defined as prostate cancer cases with low PTEN and low CRISP3, high PTEN and low CRISP3, or high PTEN and high CRISP3 expression. The association of the low- and high-risk subgroups with clinicopathological parameters, BCR and cancer-related mortality is demonstrated in [Table III](#tIII-ol-0-0-4459){ref-type="table"}. The high-risk prostate cancers were significantly correlated with high prePSA, high GS, high pT stage, LVI, metastasis, BCR and cancer-related mortality. The high-risk subgroup showed 28/49 samples (57.1%) with a GS of ≥7 vs. 5/19 samples (26.3%) with a GS of \<7 (P=0.022); 21/30 samples (70.0%) in pT3 vs. 12/38 samples (31.6%) in pT2 (P=0.002); 11/14 samples (78.6%) with LVI vs. 22/54 samples (40.7%) without LVI (P=0.012); 5/5 samples (100.0%) with metastasis vs. 26/57 samples (45.6%) without metastasis (P=0.021); 18/19 samples (94.7%) with BCR vs. 15/45 samples (33.3%) without BCR (P\<0.001); and 9/9 samples (100.0%) in decedents vs. 24/59 samples (40.7%) in living patients (P=0.001). The high-risk subgroup also presented with significantly increased prePSA levels (12.7±10.4 ng/ml) compared with those of the low-risk subgroup (7.9±4.7 ng/ml) (P=0.027) ([Table III](#tIII-ol-0-0-4459){ref-type="table"}).

The high-risk subgroup with low PTEN and high CRISP3 expression was shown to be significantly predictive of the prognosis for BCR-free survival using univariate analysis (P\<0.001; [Fig. 3](#f3-ol-0-0-4459){ref-type="fig"}) and multivariate analysis (P=0.030; [Table IV](#tIV-ol-0-0-4459){ref-type="table"}). The other factors, such as high pT stage (pT3) and metastasis, showed unfavorable trends for shorter BCR (P=0.052 and P=0.084, respectively), but these differences were not significant.

Discussion
==========

The prevalence of transmembrane protease serine 2 (TMPRSS2):ERG fusion in prostate cancer depends on genetic and ethnic differences, with a much higher prevalence in Caucasian individuals: 36--60% in USA, Germany and Canada; 48% in Brazil; 20.9--26.5% in Korea (including the present study); 23.2% in China; and 28% in Japan ([@b1-ol-0-0-4459],[@b12-ol-0-0-4459],[@b18-ol-0-0-4459]).

TMPRSS2:ERG rearrangement in prostate cancer was initially demonstrated by the microdeletion of chromosome 21 and the insertion of the deleted region into a different chromosome, resulting in TMPRSS2:ERG fusion ([@b19-ol-0-0-4459]). This fusion between the androgen-driven gene, TMPRSS2, and the oncogenic transcription factor genes of the E26 transformation-specific (ETS) family has been recognized as a critical event. Presently, 14 5′ fusion partners (TMPRSS2, SLC45A3, HERV-K, KLK2, CANT1, FOXP1, HERVK17, EST14, ELJ35294, C15orf21, HNRPA2B1, DDX5, ACSL3 and NDRG1) and 4 ETS family genes (ERG, ETV1, ETV4 and ETV5) have been found, and the TMPSS2:ERG fusion accounts for \~90% of all fusions ([@b18-ol-0-0-4459]). The majority of ETS family transcription factor genes have an 85-amino acid ETS domain that promotes binding to the specific GGAA/T core consensus sequence and regulates the expression of target genes associated with prostate cancer generation and progression ([@b20-ol-0-0-4459]). The TMPRSS2:ERG fusion protein is detected by immunohistochemistry, as ERG overexpression by immunohistochemistry is highly concordant with ERG fusion or rearrangement by reverse transcription-quantitative polymerase chain reaction or fluorescence *in situ* hybridization ([@b21-ol-0-0-4459],[@b22-ol-0-0-4459]).

The PTEN gene on chromosome 10q23 is a tumor suppressor gene, and PTEN loss releases the regulation of the receptor tyrosine kinase (RTK)/phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. PTEN loss promotes prostate cancer progression and metastasis, and is present in aggressive and hormone-refractory prostate cancer ([@b23-ol-0-0-4459]--[@b28-ol-0-0-4459]). The RTK/PI3K/Akt pathway has also been linked to cholesterol ester accumulation and chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 ([@b29-ol-0-0-4459],[@b30-ol-0-0-4459]). PTEN genomic loss (heterozygous or homozygous PTEN deletion) has been detected with an incidence of 75--86% PTEN protein loss. PTEN protein loss is significantly associated with PTEN genomic loss ([@b4-ol-0-0-4459],[@b28-ol-0-0-4459]).

CRISP3 consists of 254 amino acids and is encoded by a locus on 6p12.3. CRISP3 is an extracellular matrix protein found in the salivary glands and male reproductive tract, and its expression is driven by androgens. CRISP3 is intracellularly stored in the granules of neutrophils and eosinophils, in either a glycosylated or unglycosylated form, and is secreted for the innate host defense, resulting in cellular matrix remodeling by proteolysis ([@b31-ol-0-0-4459]--[@b33-ol-0-0-4459]). The exact function of CRISP3 requires further research.

SPINK1 is a 56-amino acid extracellular secreted protein known as a pancreatic secretory trypsin inhibitor or a tumor-associated trypsin inhibitor ([@b34-ol-0-0-4459]). SPINK1 has been detected in benign lesions and malignancies, such as colorectal, hepatocellular and breast cancer ([@b35-ol-0-0-4459]--[@b38-ol-0-0-4459]). SPINK1 in prostate cancer can induce epithelial-mesenchymal transition through the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)/MAPK kinase/extracellular signal-regulated kinase signaling pathway ([@b34-ol-0-0-4459]).

It has been documented that ERG fusion is enriched for PTEN deletion ([@b12-ol-0-0-4459]), which is consistent with the findings from the present study. PTEN loss is significantly associated with an underlying ERG rearrangement ([@b39-ol-0-0-4459]), as ERG fusion can increase the expression of nuclear factor-κB (regulator of PTEN transcription), inhibit PTEN transcription and manipulate the microenvironment to induce the chromosomal rearrangement of PTEN ([@b20-ol-0-0-4459],[@b25-ol-0-0-4459]).

ERG fusion expression is mutually exclusive of SPINK1 expression ([@b15-ol-0-0-4459]). SPINK1 overexpression is linked to prostate cancer with 6q15-and 5q21-deleted ERG fusion-negative genetic rearrangements ([@b40-ol-0-0-4459]).

It has been reported that CRISP3 protein overexpression is significantly correlated with ERG fusion-positive prostate cancers ([@b33-ol-0-0-4459],[@b41-ol-0-0-4459]). CRISP3 is a direct target of member of the ETS family, such as ERG, as it has a specific GGAA/T core consensus sequence ([@b33-ol-0-0-4459]).

One clinicopathological parameter that has been associated with ERG overexpression is low GS (\<7) ([@b1-ol-0-0-4459],[@b18-ol-0-0-4459]); however, the correlation between BCR or cancer-related mortality and ERG overexpression has shown contradictory results in previous studies ([@b12-ol-0-0-4459],[@b42-ol-0-0-4459],[@b43-ol-0-0-4459]). In the present study, ERG overexpression was not significantly associated with a low GS or cancer-related mortality. Notably, certain studies have demonstrated that ERG fusion tends to occur in early-stage prostate cancer and can be bypassed at late-stage androgen-refractory prostate cancer ([@b16-ol-0-0-4459],[@b17-ol-0-0-4459]).

It has been revealed that PTEN loss is significantly associated with a high GS, advanced pT stage, p53 accumulation ([@b23-ol-0-0-4459],[@b28-ol-0-0-4459]), BCR and cancer-related mortality ([@b4-ol-0-0-4459],[@b23-ol-0-0-4459]), while CRISP3 overexpression is also associated with a high GS, BCR and cancer-related mortality ([@b13-ol-0-0-4459],[@b14-ol-0-0-4459],[@b33-ol-0-0-4459],[@b41-ol-0-0-4459]), as shown in the present study.

It has been documented that there is a significant association between SPINK1 overexpression and BCR or cancer-related mortality, although this association was not significant in a few studies (including the present study) ([@b44-ol-0-0-4459]). The present study showed that a high PSA level was not significantly associated with high SPINK1 expression (P=0.09; [Table II](#tII-ol-0-0-4459){ref-type="table"}). Based on this result, we speculate that SPINK1 overexpression decreases BCR-free survival.

Briefly, ERG fusion is central in the regulation of PTEN, CRISP3 and SPINK1 expression. This fusion is a pathognomonically important event in prostate cancer pathogenesis. PTEN loss and increased CRISP3 expression can be promoted by positive ERG expression. SPINK1 expression is mutually exclusive of ERG expression.

PTEN loss and the high expression of CRISP3 can be unfavorable prostate cancer indicators, as PTEN loss is associated with a shorter BCR and with hormone-refractory prostate cancer. A high level of CRISP3 expression also increases BCR and cancer-related mortality. The loss of PTEN or CRISP3 overexpression may be used as a better predictor of progressed (advanced) prostate cancer than ERG fusion expression, although is does not provide significant results for BCR. However, a single biomarker of either PTEN or CRISP3 is insufficient to predict the prognosis for BCR. For this reason, combined PTEN and CRISP3 expression may be used with regard to patients with a poor prognosis. Categorizing patients into high- and low-risk subgroups is well correlated with BCR-free survival in prostate cancer, as aforementioned in the present study ([Table III](#tIII-ol-0-0-4459){ref-type="table"}; [Fig. 3](#f3-ol-0-0-4459){ref-type="fig"}).

In conclusion, the present study suggests that low PTEN expression and high CRISP3 expression significantly characterize the subgroups of prostate cancer with a poor prognosis for BCR. These results will aid in the management and stratification of patients with advanced prostate cancer.

The abstract was presented at the United States & Canadian Academy of Pathology 104th Annual Meeting Abstracts and published in Modern Pathol (Suppl 2s): 247A-248A, 2015.

![Immunohistochemical analysis of ERG, PTEN, CRISP3 and SPINK1. Original magnification, ×200. (A) ERG expression is based on nuclear staining and classified as negative, weak, moderate and strong. (B) PTEN expression shows cytoplasmic staining classified as a 3-tiered system, and a mixed pattern is also noted. (C) CRISP3 expression is evaluated as cytoplasmic staining categorized as negative, weak, moderate and strong. (D) SPINK1 expression is assessed as negative and positive cytoplasmic staining. ERG, transcriptional regulator ERG; PTEN, phosphatase and tensin homolog; CRISP3, cysteine-rich secretory protein 3; SPINK1, serine protease inhibitor Kazal type I.](ol-11-06-3621-g00){#f1-ol-0-0-4459}

![Univariate analysis (Kaplan-Meier curves) of biochemical recurrence (BCR)-free survival in association with (A) Gleason score, (B) pathological tumor (pT) stage and (C) metastasis, and expression of (D) transcriptional regulator ERG (ERG), (E) phosphatase and tensin homolog (PTEN), (F) cysteine-rich secretory protein 3 (CRISP3) and (G) serine protease inhibitor Kazal type I (SPINK1).](ol-11-06-3621-g01){#f2-ol-0-0-4459}

![Univariate analysis (Kaplan-Meier curve) for low-risk and high-risk subgroups. BCR, biochemical recurrence.](ol-11-06-3621-g02){#f3-ol-0-0-4459}

###### 

Demographics of the prostate cancer samples.

  Clinicopathological parameters                                 Value
  -------------------------------------------------------------- ------------
  Age in years, n (%)                                            
    \<50                                                           9 (13.2)
    50--59                                                       38 (55.9)
    \>60                                                         21 (30.9)
  Pretreatment PSA in ng/ml, n (%)                               
    \<4                                                          8 (11.8)
    4--10                                                        31 (45.6)
    10--20                                                       18 (26.5)
    \>20                                                         5 (7.4)
  Tumor volume %, n (%)                                          
    \<5                                                          19 (27.9)
    5--10                                                        13 (19.1)
    10--20                                                       12 (17.6)
    20--50                                                       14 (20.6)
    \>50                                                         4 (5.9)
  Gleason score, n (%)                                           
    \<7                                                          19 (27.9)
    =7                                                           36 (52.9)
    \>7                                                          13 (19.1)
  pT stage^[a](#tfn1-ol-0-0-4459){ref-type="table-fn"}^, n (%)   
    pT2                                                          38 (55.9)
    pT3                                                          30 (44.1)
  Surgical margin, n (%)                                         
    Negative                                                     46 (67.6)
    Positive                                                     22 (32.4)
  Lymphovascular invasion, n (%)                                 
    Absent                                                       54 (79.4)
    Present                                                      14 (20.6)
  Perineural invasion, n (%)                                     
    Absent                                                       37 (54.4)
    Present                                                      31 (45.6)
  Metastasis, n (%)                                              
    Absent                                                       57 (83.8)
    Present                                                      5 (7.4)
  Biochemical recurrence, n (%)                                  
    Absent                                                       45 (66.2)
    Present                                                      17 (25.0)
  Mortality, n (%)                                               
    Alive                                                        59 (86.8)
    Succumbed                                                    9 (13.2)
  Follow-up, months                                              
    Range                                                        11--111
    Mean                                                         49.2

American Joint Committee on Cancer 2010 criteria. pT stage, pathological T stage; PSA, prostatic-specific antigen.

###### 

Association of the clinicopathological parameters, BCR and cancer-related mortality with ERG, PTEN, CRISP3 and SPINK1 expression.

                                                                   ERG                         PTEN                                                                   CRISP3                                                                SPINK1                                                                                                             
  ---------------------------------------------------------------- -------------- ------------ -------------------------------------------------------- ------------- ------------ -------------------------------------------------------- ------------ -------------- ---------------------------------------------------------- -------------- ------------ --------------------------------------------------------
  Age, years^[a](#tfn2-ol-0-0-4459){ref-type="table-fn"}^          65.7±5.3       66.8±6.4     0.468                                                    65.3±5.7      68.2±4.6     0.065                                                    66.5±4.7     65.6±6.1       0.529                                                      66.9±5.5       63.9±5.3     0.041
  prePSA, ng/ml^[a](#tfn2-ol-0-0-4459){ref-type="table-fn"}^       10.4±7.5       9.4±10.3     0.730                                                    10.8±8.9      8.3±5.2      0.303                                                    7.9±4.6      11.6±9.6       **0.045**                                                  8.8±6.9        13.2±10.0    0.090
  TV, %^[a](#tfn2-ol-0-0-4459){ref-type="table-fn"}^               17.9±19.7      17.3±14.5    0.900                                                    20.4±19.2     8.8±11.3     **0.035**                                                20.1±19.4      16.3±17.6      0.419                                                    15.4±15.5      22.8±22.7    0.134
  GS, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                       0.575                                                                               **0.020**                                                                            0.595                                                                                  0.772
    \<7                                                            13 (68.4)        6 (31.6)                                                            11 (57.9)       8 (42.1)                                                              9 (47.4)   10 (52.6)                                                                 13 (68.4)        6 (31.6)   
    =7                                                             26 (72.2)      10 (27.8)                                                             29 (80.6)       7 (19.4)                                                            12 (33.3)    24 (66.7)                                                                 26 (72.2)      10 (27.8)    
    \>7                                                            11 (84.6)        2 (15.4)                                                            12 (92.3)     1 (7.7)                                                                 5 (38.5)     8 (61.5)                                                                  8 (61.5)       5 (38.5)   
  pT stage, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                 0.558                                                                               0.236                                                                                **0.025**                                                                              0.697
    pT2                                                            29 (76.3)        9 (23.7)                                                            27 (71.1)     11 (28.9)                                                             19 (50.0)    19 (50.0)                                                                 27 (71.1)      11 (28.9)    
    pT3                                                            21 (70.0)        9 (30.0)                                                            25 (83.3)       5 (16.7)                                                              7 (23.3)   23 (76.7)                                                                 20 (66.7)      10 (33.3)    
  Margin, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                   0.628                                                                               0.472                                                                                0.826                                                                                  0.216
    Negative                                                       33 (71.7)      13 (28.3)                                                             34 (73.9)     12 (26.1)                                                             18 (39.1)    28 (60.9)                                                                 34 (73.9)      12 (26.1)    
    Positive                                                       17 (77.3)        5 (22.7)                                                            18 (81.8)       4 (18.2)                                                              8 (36.4)   14 (63.6)                                                                 13 (59.1)        9 (40.9)   
  LVI, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                      0.379                                                                               0.105                                                                                0.146                                                                                  0.834
    Absent                                                         41 (75.9)      13 (24.1)                                                             39 (72.2)     15 (27.8)                                                             23 (42.6)    31 (57.4)                                                                 37 (68.5)      17 (31.5)    
    Present                                                          9 (64.3)       5 (35.7)                                                            13 (92.9)     1 (7.1)                                                                 3 (21.4)   11 (78.6)                                                                 10 (71.4)        4 (28.6)   
  PNI, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                      0.322                                                                               0.458                                                                                0.282                                                                                  0.452
    Absent                                                         29 (78.4)        8 (21.6)                                                            27 (73.0)     10 (27.0)                                                             12 (32.4)    25 (67.6)                                                                 27 (73.0)      10 (27.0)    
    Present                                                        21 (67.7)      10 (32.3)                                                             25 (80.6)       6 (19.4)                                                            14 (45.2)    17 (54.8)                                                                 20 (64.5)      11 (35.5)    
  Metastasis, n (%)^[d](#tfn5-ol-0-0-4459){ref-type="table-fn"}^                               0.449^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                  0.191^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^                                   0.086^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^                                     0.636^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^
    Absent                                                         43 (75.4)      14 (24.6)                                                             42 (73.7)     15 (26.3)                                                             22 (38.6)    35 (61.4)                                                                 40 (70.2)      17 (29.8)    
    Present                                                          3 (60.0)       2 (40.0)                                                              5 (100.0)     0 (0.0)                                                             0 (0.0)        5 (100.0)                                                                 3 (60.0)       2 (40.0)   
  BCR, n (%)^[d](#tfn5-ol-0-0-4459){ref-type="table-fn"}^                                      0.691^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                  **0.039^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^**                               **\<0.001^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^**                               0.275^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^
    Absent                                                         34 (75.6)      11 (24.4)                                                             31 (68.9)     14 (31.1)                                                             22 (48.9)    23 (51.1)                                                                 30 (66.7)      15 (33.3)    
    Present                                                        12 (70.6)        5 (29.4)                                                            16 (94.1)     1 (5.9)                                                               0 (0.0)        17 (100.0)                                                              15 (78.9)        4 (21.1)   
  Mortality, n (%)                                                                             0.189^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                  0.076^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^                                   **0.011^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^**                                 0.846^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^
    Alive                                                          45 (76.3)      14 (23.7)                                                             43 (72.9)     16 (27.1)                                                             26 (44.1)    33 (55.9)                                                                 41 (69.5)      18 (30.5)    
    Succumbed                                                        5 (55.6)       4 (44.4)                                                              9 (100.0)   0 (0.0)                                                                 0 (0.0)      9 (100.0)                                                                 6 (66.7)       3 (33.3)   
  ERG, n (%)                                                                                                                                                                       **0.036^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^**                               0.103^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                     **0.001^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^**
    Neg.                                                                                                                                                35 (70.0)     15 (30.0)                                                             22 (44.0)    28 (56.0)                                                                 29 (58.0)      21 (42.0)    
    Pos.                                                                                                                                                17 (94.4)     1 (5.6)                                                                 4 (22.2)   14 (77.8)                                                                   18 (100.0)   0 (0.0)      
  PTEN, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                     **0.036**                                                                                                                                                                0.604                                                                                  0.203
    Low                                                            35 (67.3)      17 (32.7)                                                                                                                                                 19 (36.5)    33 (63.5)                                                                 38 (73.1)      14 (26.9)    
    High                                                           15 (93.8)      1 (6.3)                                                                                                                                                   7 (43.8)       9 (56.3)                                                                  9 (56.3)       7 (43.8)   
  CRISP3, n (%)^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                   0.103                                                                               0.604                                                                                                                                                                       0.600
    Low                                                            22 (84.6)        4 (15.4)                                                            19 (73.1)     7 (26.9)                                                                                                                                                     17 (65.4)        9 (34.6)   
    High                                                           28 (66.7)      14 (33.3)                                                             33 (78.6)     9 (21.4)                                                                                                                                                     30 (71.4)      12 (28.6)    
  SPINK1, n (%)                                                                                **0.001^[c](#tfn4-ol-0-0-4459){ref-type="table-fn"}^**                              0.203^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                   0.600^[b](#tfn3-ol-0-0-4459){ref-type="table-fn"}^                                     
    Neg.                                                           29 (61.7)      18 (38.3)                                                             38 (80.9)     9 (19.1)                                                              17 (36.2)    30 (63.8)                                                                                             
    Pos.                                                             21 (100.0)   0 (0.0)                                                               14 (66.7)     7 (33.3)                                                                9 (42.9)   12 (57.1)                                                                                             

Student\'s t-test, data are presented as mean ± standard deviation

χ^2^ test

Fisher\'s exact test.

Patients with discontinued follow-up or unavailable data were excluded. Values in bold are P\<0.05. BCR, biochemical recurrence; CRISP3, cysteine-rich secretory protein 3; ERG, transcriptional regulator ERG; GS, Gleason score; LVI, lymphovascular invasion; Neg., negative; PNI, perineural invasion; Pos., positive; prePSA, pretreatment prostate-specific antigen; pT stage, pathological T stage; PTEN, phosphatase and tensin homolog; SPINK1, serine protease inhibitor Kazal type I; TV, tumor volume.

###### 

Associations of the clinicopathological parameters with the low- and high-risk subgroups.

  Parameters                                                            Low-risk^[a](#tfn6-ol-0-0-4459){ref-type="table-fn"}^   High-risk^[b](#tfn7-ol-0-0-4459){ref-type="table-fn"}^   P-value
  --------------------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- -------------
  Age, years^[c](#tfn8-ol-0-0-4459){ref-type="table-fn"}^               67.0±4.9                                                64.8±6.0                                                   0.101
  prePSA, ng/ml^[c](#tfn8-ol-0-0-4459){ref-type="table-fn"}^              7.9±4.7                                                 12.7±10.4                                                **0.027**
  Tumor volume, %^[c](#tfn8-ol-0-0-4459){ref-type="table-fn"}^            16.1±18.3                                               19.5±18.5                                                0.468
  Gleason score, n (%)^[d](#tfn9-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                        0.069
    \<7                                                                 14 (73.7)                                                 5 (26.3)                                               
    =7                                                                  16 (44.4)                                               20 (55.6)                                                
    \>7                                                                   5 (38.5)                                                8 (61.5)                                               
  pT stage, n (%)^[d](#tfn9-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                             **0.002**
    pT2                                                                 26 (68.4)                                               12 (31.6)                                                
    pT3                                                                   9 (30.0)                                              21 (70.0)                                                
  Surgical margin, n (%)^[d](#tfn9-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                      0.867
    Negative                                                            24 (52.2)                                               22 (47.8)                                                
    Positive                                                            11 (50.0)                                               11 (50.0)                                                
  LVI, n (%)^[d](#tfn9-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                                  **0.012**
    Absent                                                              32 (59.3)                                               22 (40.7)                                                
    Present                                                               3 (21.4)                                              11 (78.6)                                                
  PNI, n (%)^[d](#tfn9-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                                  0.983
    Absent                                                              19 (51.4)                                               18 (48.6)                                                
    Present                                                             16 (51.6)                                               15 (48.4)                                                
  Metastasis, n (%)^[e](#tfn10-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                          **0.021**
    Absent                                                              31 (54.4)                                               26 (45.6)                                                
    Present                                                             0 (0.0)                                                   5 (100.0)                                              
  BCR, n (%)^[d](#tfn9-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                                **\<0.001**
    Absent                                                              30 (66.7)                                               15 (33.3)                                                
    Present                                                             1 (5.3)                                                 18 (94.7)                                                
  Mortality, n (%)^[e](#tfn10-ol-0-0-4459){ref-type="table-fn"}^                                                                                                                           **0.001**
    Alive                                                               35 (59.3)                                               24 (40.7)                                                
    Dead                                                                0 (0.0)                                                   9 (100.0)                                              

Low risk: Low PTEN and low CRISP3, high PTEN and low CRISP3, and high PTEN and high CRISP3 expression.

High risk: Low PTEN and high CRISP3 expression.

Student\'s t-test, data are presented as mean ± standard deviation.

χ^2^ test.

Fisher\'s exact test. BCR, biochemical recurrence; CRISP3, cysteine-rich secretory protein 3; PNI, perineural invasion; prePSA, pretreatment prostate-specific antigen; PTEN, phosphatase and tensin homolog; LVI, lymphovascular invasion.

###### 

Multivariate analysis (Cox\'s proportional hazard model).

                                                                                                                                 95% CI                                       
  ------------------------------------------------------------------------------------------------------------------------------ -------- ------- ----------- ------- ------- ---------
  Subgroup, high-risk^[a](#tfn11-ol-0-0-4459){ref-type="table-fn"}^ vs. low-risk^[b](#tfn12-ol-0-0-4459){ref-type="table-fn"}^   2.300    1.062   **0.030**   9.979   1.244   80.031
  pT stage, pT3 vs. pT2                                                                                                          2.040    1.048   0.052       7.687   0.985   59.996
  Metastasis, present vs. absent                                                                                                 1.013    0.586   0.084       2.754   0.873     8.682

High risk: Low PTEN and high CRISP3 expression.

Low risk: Low PTEN and low CRISP3, high PTEN and low CRISP3, and high PTEN and high CRISP3 expression. B, regression coefficient; CI, confidence interval; HR, hazard ratio; SE, standard error; pT, pathological T stage.
